Among US men, prostate cancer (PC) accounts for 29% of all newly diagnosed cancers. A
reliable scintigraphic agent to image PC and its metastatic or recurrent lesions and to …

Objective To evaluate 64 Cu-TP3805 as a novel biomolecule, to positron emission
tomography (PET) image prostate cancer (PC), at the onset of which VPAC1, the superfamily …

The purpose of this study was to assess the feasibility of PET imaging of oncogene VPAC1
receptors overexpressed in human breast cancer cells. Methods: Vasoactive intestinal …

VPAC1 encodes G-protein–coupled receptors expressed on all breast cancer (BC) cells at
the onset of the disease, but not on benign lesions. Our extensive preclinical studies have …

Vasoactive intestinal peptide (VIP) is involved in prostate cell proliferation and function. VIP
and pituitary adenylate cyclase-activating peptide (PACAP) are similarly recognized by …

We characterized the expression and localization of pituitary adenylate cyclase‐activating
polypeptide (PACAP) and its specific type I receptor variants in prostatic, hyperplastic, and …

Objective To validate a hypothesis that prostate cancer can be detected non‐invasively by a
simple and reliable assay by targeting genomic VPAC receptors expressed on malignant …

The evaluation of peptide receptors in man is relevant to identifying the physiological target
tissues of a given peptide and to selecting diseases with a sufficient receptor overexpression …

Our objective was to evaluate the biodistribution, kinetics, and radiation dosimetry of
64CuCl2 in humans and to assess the ability of 64CuCl2 PET/CT to detect prostate cancer …

Human tumors frequently overexpress receptors for vasoactive intestinal peptide (VIP) and
pituitary adenylate cyclase-activating peptide (PACAP). However, none of the VIP/PACAP …